Top

Published in:

01-11-2018 | Literatur kommentiert

Gibt es einen Zusammenhang zwischen zirkulierenden Tumorzellen und dem Nutzen einer Strahlentherapie bei Brustkrebs im Frühstadium?

Author: PD Dr. med. Marciana Nona Duma

Published in: Strahlentherapie und Onkologie | Issue 11/2018

Auszug

Zirkulierende Tumorzellen („circulating tumor cells“, CTC) sind ein Surrogatmarker für die Resttumorlast. Auch wenn der CTC-Status potenziell das Rezidivrisiko und das Risiko, an Brustkrebs zu versterben, vorhersagen kann, ist seine Relevanz im klinischen Alltag nach wie vor unklar. Die aktuelle, hier kommentierte Studie untersucht den strahlentherapeutischen Nutzen in Abhängigkeit vom CTC-Status bei Brustkrebspatientinnen im Frühstadium. …

Fisher B et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241CrossRef

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716CrossRef

Hughes KS et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31(19):2382–2387CrossRef

Kunkler IH et al (2015) Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 16(3):266–273CrossRef

Blamey RW et al (2013) Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 49(10):2294–2302CrossRef

Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) (2017) Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/LL_Mammakarzinom_Langversion_4.0.pdf. Zugegriffen: 19.07.2018

Sparano JA et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014CrossRef

Cardoso F et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729CrossRef

Martin M et al (2014) Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res 16(2):R38CrossRef

10.

Dubsky P et al (2013) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 24(3):640–647CrossRef

11.

Buus R et al (2016) Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw149 CrossRefPubMedPubMedCentral

12.

ClinicalTrials.gov. (2018) The IDEA Study (individualized decisions for endocrine therapy alone). https://clinicaltrials.gov/ct2/show/NCT02400190. Zugegriffen: 19.07.2018

13.

ClinicalTrials.gov. (2018) The PRECISION Trial (profiling early breast cancer for radiotherapy omission): a phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer. https://www.clinicaltrials.gov/ct2/show/NCT02653755. Zugegriffen: 19.07.2018

14.

ClinicalTrials.gov. (2018) A prospective cohort study evaluating risk of local recurrence following breast conserving surgery and endocrine therapy in low risk luminal A breast cancer (LUMINA). https://clinicaltrials.gov/ct2/show/NCT01791829. Zugegriffen: 19.07.2018

15.

Rack B et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju066 CrossRefPubMedPubMedCentral

Title: Gibt es einen Zusammenhang zwischen zirkulierenden Tumorzellen und dem Nutzen einer Strahlentherapie bei Brustkrebs im Frühstadium?
Author: PD Dr. med. Marciana Nona Duma
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 11/2018
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1370-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gibt es einen Zusammenhang zwischen zirkulierenden Tumorzellen und dem Nutzen einer Strahlentherapie bei Brustkrebs im Frühstadium?

Auszug

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 11/2018

Treatment of malnutrition decreases complication rates and shortens the length of hospital stays in a radiation oncology department

Accuracy assessment of a potential clinical use of navigation-guided intra-operative liver metastasis brachytherapy—a planning study

Age-corrected hearing loss after chemoradiation in cervical cancer patients

Radiation-induced morphea—a rare but severe late effect of adjuvant breast irradiation

Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer

A treatment planning study of prone vs. supine positions for locally advanced rectal carcinoma